Liquidia Corporation (LQDA) shares climbed 5.0% to $28.02 as of October 9, 2026, a significant gain from the prior close of $26.68. BestStocks flagged the session as a major change for LQDA. The move is tied to company news. Below, we break down what changed for LQDA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
Liquidia Corporation shares rose 7.7% on September 28, 2026, driven by positive momentum in specialty biotech peers and renewed investor confidence in the commercial prospects for its flagship drug YUTREPIA. The rally reflected broader sector strength rather than company-specific news on the session.
For Liquidia Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 5.0% price move with conviction. Weighing against that: Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today; Liquidia Corporation fell 6.46% to $73.70 following the filing of an earnings report and a material event (8-K) disclosed today, per SEC filings. Wall Street's consensus price target sits at $83.20, implying +196.9% upside from $28.02. BestStocks rates the overall signal quality medium (68/100). With earnings roughly 24 days out, the next report is the most likely near-term test of the move.
LQDA price reaction
LQDA last traded at $28.02, up $1.34 (+5.02%) from the previous close of $26.68. The session traded on 2.2× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $25.91 and $73.67, and it currently sits about 4% of the way up that band.
Bullish and bearish analyst opinions on Liquidia Corporation (LQDA)
The consensus analyst price target on Liquidia Corporation (LQDA) is $83.20, 196.9% above the recent $28.02. Here is how the bullish and bearish cases on LQDA line up.
▲ The bullish case
+Wall Street's consensus price target of $83.20 implies +196.9% upside from $28.02.
+The Street's most bullish target is $130.00 (+364.0%).
+Material positive event.
+Strong 5.0% price move with conviction.
+Volume 2.2x average — institutional conviction.
▼ The bearish case
−Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today.
−Liquidia Corporation shares fell 8.14% to $80.88 following today's earnings report filing and a same-day material event disclosure (8-K).
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
LQDA rebounded +8.70% to $29.00 following a sharp late-September sell-off tied to an adverse Delaware federal court ruling in its patent dispute with United Therapeutics over YUTREPIA. The web search indicates the move reflects technical oversold bounce and value-driven bargain hunting after the ~57% crash, despite ongoing legal overhang and a pending shareholder class-action investigation (Globe Newswire, Benzinga). Volume was elevated at 2.14x the time-adjusted average, consistent with recovery trading.
News2026-10-07+3.0%
Law firm Bragar Eagel & Squire initiates investigation into Liquidia Corporation on behalf of stockholders.
News2026-10-06-6.3%
Law firm Kirby McInerney initiates securities investigation into LQDA for potential federal violations by company and senior management.
Material / Earnings2026-10-06-6.3%
Liquidia Corporation (LQDA) moved -7.30% on October 6, 2026, after a federal court ruled that its lead drug Yutrepia infringes two valid patent claims held by United Therapeutics under the '327 patent. The decision prompted multiple analyst downgrades: Wells Fargo cut the stock to equal weight with a $30 price target, BTIG downgraded to Neutral from Buy, Raymond James slashed its target to $53 from $106, and BofA lowered its target to $40 from $92, all citing commercial uncertainty around the pulmonary hypertension drug.
Liquidia shares fell 4.81% to $27.26 following a September 30 Delaware federal court ruling that its lead drug Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for pulmonary hypertension with interstitial lung disease (PH-ILD), per Raymond James and BofA analyst downgrades cited on Yahoo Finance. Major Wall Street firms cut price targets amid concern over potential sales injunctions or forced label changes limiting Yutrepia's market. Volume was elevated at 1.60x historical average at the 360-minute mark.
Material / Earnings2026-10-02+2.3%
Liquidia Corporation (LQDA) moved +7.31% from $26.69 to $28.64 on 2026-10-02, one day after a patent court ruling threatened Yutrepia's pulmonary hypertension–interstitial lung disease (PH-ILD) indication. The stock had plunged 57% on 2026-10-01 following the adverse ruling; the +7.31% move on 2026-10-02 represents a partial recovery from that sharp decline.
Risk2026-10-01-7.5%
Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today. The specific contents of the filing were not immediately disclosed in available sources, but the sharp intraday decline suggests investors reacted negatively to the disclosed event.
Material / Earnings2026-10-01-7.5%
Liquidia Corporation (LQDA) moved +16.55% from $24.02 to $27.99 on 2026-10-01, with volume 3.9x the 5-day average. News highlighted YUTREPIA adoption generating profits and cash flow, establishing an operating foundation for growth, and a District Court ruling that two of six patent claims against Liquidia were valid and infringed, with remedy determination pending.
In-depth LQDA event analyses
Permanent, dated analyses of LQDA's most significant sessions.
Liquidia Corporation shares rose 7.7% on September 28, 2026, driven by positive momentum in specialty biotech peers and renewed investor confidence in the commercial prospects for its flagship drug YUTREPIA. The rally reflected broader sector strength rather than company-specific news on the session.
How much did LQDA stock rise?
LQDA gained 5.02% ($1.34) versus the prior close of $26.68, last trading at $28.02 on 2.2× average volume.
When is Liquidia Corporation's next earnings date?
LQDA's next earnings report is estimated for 2026-11-02 — about 24 days away.
What is the analyst price target for LQDA?
The consensus analyst price target for LQDA is $83.20, about 196.9% above the current $28.02. Over the past 90 days, analysts recorded 0 upgrades, 0 maintains, and 0 downgrades.
How BestStocks tracks LQDA
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for LQDA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
